# To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

> **NCT06194448** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 76 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Osimertinib
- **DRUG:** Cisplatin or Carboplatin; Pemetrexed or Paclitaxel
- **DRUG:** Radiation

## Key facts

- **NCT ID:** NCT06194448
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-21
- **Primary completion:** 2026-07-07
- **Final completion:** 2027-07-07
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06194448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06194448, "To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06194448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*